News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
A new weapon in the global fight against malaria
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Asahi Kasei Life Science covers a broad range of bioprocess products and services
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Founded in 2023, Spectrum Vascular acquired the vascular access businesses of Cook Medical in 2023 and AngioDynamics in 2024
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Subscribe To Our Newsletter & Stay Updated
